BioCryst Pharmaceuticals, Inc. BCRX
NASDAQ · United States · Health Technology
$8.18-0.15 (-1.80%)
Market open· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market open· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
| Quarter | Report date | Actual EPS | Estimated EPS | EPS surprise | Actual revenue | Revenue surprise | Price reaction |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 2026-08-05 | 0.30 | 0.15 | +94.6% | $218.25M | +19.1% | +3.1%$9.02→$9.30 |
| Q1 2026 | 2026-05-06 | 0.14 | 0.11 | +27.3% | — | — | -1.4%$9.03→$8.90 |
| Q4 2025 | 2026-02-26 | 0.21 | 0.07 | +200.0% | — | — | +15.9%$7.55→$8.75 |
| Q3 2025 | 2025-11-03 | 0.16 | 0.07 | +128.6% | — | — | -7.7%$7.32→$6.76 |
| Q2 2025 | 2025-08-04 | 0.04 | 0.03 | +33.3% | — | — | — |
| Q1 2025 | 2025-05-05 | 0.00 | -0.05 | +100.0% | — | — | — |
| Q4 2024 | 2025-02-24 | -0.13 | -0.06 | -116.7% | — | — | — |
| Q3 2024 | 2024-11-04 | -0.07 | -0.08 | +12.5% | — | — | — |
The price reaction is the change from the last close before the announcement date to the first close after it - the report may land before the open, during the session or after the close, so this window covers all three. Not investment advice.